Topic
Xanthone
About: Xanthone is a research topic. Over the lifetime, 1639 publications have been published within this topic receiving 25870 citations. The topic is also known as: 9-oxo-xanthene & Diphenyline ketone oxide.
Papers published on a yearly basis
Papers
More filters
TL;DR: The route to biologically active xanthone and fluorenone analogs proceeds smoothly for substrates equipped with electron-donating substituents, but leads to no reaction or trace amounts of products for substrate with electron -withdrawing groups.
Abstract: The route to biologically active xanthone and fluorenone analogs proceeds smoothly for substrates equipped with electron-donating substituents, but leads to no reaction or trace amounts of products for substrates with electron-withdrawing groups.
1 citations
Journal Article•
1 citations
Patent•
09 Feb 2011
TL;DR: In this article, a new methylenedioxy xanthone compound and anti-tumor effect thereof was proposed. But the application of the compound in preparation of a medicament was not discussed.
Abstract: The invention relates to a new methylenedioxy xanthone compound and anti-tumor effect thereof. The invention also relates to application of the compound in preparation of a medicament, particularly preparation of an anti-tumor medicament.
1 citations
Patent•
10 Mar 1988
1 citations
TL;DR: A final in silico prediction of skin metabolism of compound 3 seems promising, indicating stability of the xanthone moiety in the metabolism process, as well as safety and antibacterial activity against Salmonella at all higher concentrations.
Abstract: Ten new xanthone derivatives have been designed and synthesized for their potential antibacterial activity. All compounds have been screened against Staphylococcus epidermidis strains ATCC 12228 and clinical K/12/8915. The highest antibacterial activity was observed for compound 3: 5-chloro-2-((4-(2-hydroxyethyl)piperazin-1-yl)methyl)-9H-xanthen-9-one dihydrochloride, exhibiting MIC of 0.8 µg/ml against ATCC 12228 strain, compared to linezolid (0.8 µg/ml), ciprofloxacin (0.2 µg/ml) or trimethoprim and sulfamethoxazole (0.8 µg/ml). For the most active compound 3, genotoxicity assay with use of Salmonella enterica serovar Typhimurium revealed safety in terms of genotoxicity at concentration 75 µg/ml and antibacterial activity against Salmonella at all higher concentrations. A final in silico prediction of skin metabolism of compound 3 seems promising, indicating stability of the xanthone moiety in the metabolism process.
1 citations